Benzodiazepine-Based Drug Discovery
- 1st Edition - August 16, 2022
- Imprint: Elsevier
- Authors: Farzad Zamani, Esmail Doustkhah
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 5 1 6 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 6 0 1 0 - 9
Benzodiazepine-Based Drug Discovery covers benzodiazepines and benzothiazepines, which constitute two pivotal classes of heterocyclic compounds widely used as core structure… Read more
Purchase options
Benzodiazepine-Based Drug Discovery covers benzodiazepines and benzothiazepines, which constitute two pivotal classes of heterocyclic compounds widely used as core structures of medicinal drugs for the treatment of depression, epilepsy, seizures and muscle spasms. 1,4-Benzodiazepine, 1,5-benzodiazepine, and 1,5-benzothiazepine are the most studied groups of benzodiazepines and benzothiazepines because of their outstanding potential biological activities. This book offers a broad range of recent developments and detailed coverage of the synthesis and biological activities of the drugs based on benzodiazepine and benzothiazepine matrixes, and is an ideal reference guide to researchers working in organic and medicinal chemistry.
The importance of these privileged pharmacophores is not limited to the treatment of psychotic disorders because minor changes in the structures can generate various biological activities. They represent a wide range of therapeutic functions such as anticonvulsant, antianxiety, anti-depressant, antiviral, anti-HIV, anti-inflammatory, anticoagulant, anti-obesity, endothelin antagonist, cholecystokinin antagonist, and vasopressin receptor antagonist activities.
- Presents detailed coverage of chemical structures and practical synthetic methods of benzodiazepines and benzothiazepines in drug discovery
- Compiles detailed in vivo and in vitro biological activity data of 1,4-benzodiazepine- and 1,5-benzodiazepine-based drugs that will help researchers design and develop innovative drugs
- Discusses promising avenues and potential challenges in the development of new benzodiazepines and benzothiazepines in medicinal drug synthesis
Researchers in organic chemistry both in academic and industrial settings, postgraduates in chemistry and medicinal chemistry
1. An Introduction to Benzodiazepines
2. Chemical Structure of 1,4-Benzodiazepines
3. Synthesis of 1,4-Benzodiazepines
4. Biological Behavior of 1,4-Benzodiazepines
5. Pharmaceutical Applications of 1,4-Benzodiazepines
5.1- Short-acting Benzodiazepines
Midazolam (Versed)
Alprazolam (Xanax)
Triazolam (Halcion)
Clorazepate (Tranxene)
5.2. Intermediate-acting Benzodiazepines
Estazolam (ProSom)
lorazepam (Ativan)
Temazepam (Restoril)
5.3. Long-acting Benzodiazepines
Clonazepam (Klonopin)
Chlordiazepoxide (Librium)
Flurazepam (Dalmane)
Diazepam (Valium)
Quazepam (Doral)
6. Chemical Structure of 1,5-Benzodiazepines and 1,5-Benzothiazepines
7. Synthesis of 1,5-Benzodiazepines and 1,5-Benzothiazepines
8. Biological Behavior of 1,5-Benzodiazepines and 1,5-Benzothiazepines
9. Pharmaceutical Applications of 1,5-Benzodiazepines
Clobazam (Onfi)
10. Pharmaceutical Applications of 1,5-Benzothiazepines
10.1. Diltiazem
10.2. Clentiazem
10.3. Thiazesim
10.4. Quetiapine
10.5. Clothiapine
- Edition: 1
- Published: August 16, 2022
- Imprint: Elsevier
- Language: English
FZ
Farzad Zamani
Farzad Zamani obtained his PhD from University of Wollongong (Australia) in 2019 under the supervision of Professor Stephen Pyne and Dr. Christopher Hyland. His research included development of transition metal-catalyzed cyclization reactions and heterocycle synthesis. Currently, he is a JSPS postdoctoral fellow in the group of Professor Takayoshi Suzuki at Osaka University working on investigation of small molecule inhibitors of RNA/epigenetic protein complexes in drug discovery.Farzad Zamani obtained his PhD from University of Wollongong (Australia) in 2019 under the supervision of Professor Stephen Pyne and Dr. Christopher Hyland. His research included development of transition metal-catalyzed cyclization reactions and heterocycle synthesis. Currently, he is a JSPS postdoctoral fellow in the group of Professor Takayoshi Suzuki at Osaka University working on investigation of small molecule inhibitors of RNA/epigenetic protein complexes in drug discovery.
Affiliations and expertise
JSPS Postdoctoral Fellow, Osaka University, JapanED
Esmail Doustkhah
Esmail Doustkhah received his PhD in 2017 in the field of catalysis and organic chemistry. In his PhD, he received several awards and scholarships. Currently, he is a JSPS fellow at NIMS in the group of Professors Y. Yamauchi and Y. Ide. His research areas include silicate nanosheet, mesoporous materials, and titania nanostructures for (photo)(bio)catalysis.
Affiliations and expertise
JSPS Postdoctoral Fellow, Osaka University, JapanRead Benzodiazepine-Based Drug Discovery on ScienceDirect